These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 24410482)

  • 1. Harnessing proteasome dynamics and allostery in drug design.
    Gaczynska M; Osmulski PA
    Antioxid Redox Signal; 2014 Dec; 21(17):2286-301. PubMed ID: 24410482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Protein-Protein Interactions in the Proteasome Super-Assemblies.
    Gaczynska M; Osmulski PA
    Curr Top Med Chem; 2015; 15(20):2056-67. PubMed ID: 25986687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pipecolic esters as minimized templates for proteasome inhibition.
    Giletto MB; Osmulski PA; Jones CL; Gaczynska ME; Tepe JJ
    Org Biomol Chem; 2019 Mar; 17(10):2734-2746. PubMed ID: 30778435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Peptide-Based Pharmacophore Activates 20S Proteasome.
    Osmulski PA; Karpowicz P; Jankowska E; Bohmann J; Pickering AM; Gaczyńska M
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32235805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-range allosteric regulation of the human 26S proteasome by 20S proteasome-targeting cancer drugs.
    Haselbach D; Schrader J; Lambrecht F; Henneberg F; Chari A; Stark H
    Nat Commun; 2017 May; 8():15578. PubMed ID: 28541292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of noncompetitive regulators of proteasome activity.
    Gaczynska M; Osmulski PA
    Methods Enzymol; 2005; 398():425-38. PubMed ID: 16275348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrocyclic proteasome inhibitors.
    Krahn D; Ottmann C; Kaiser M
    Curr Med Chem; 2011; 18(33):5052-60. PubMed ID: 22050753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric regulators of the proteasome: potential drugs and a novel approach for drug design.
    Tan X; Osmulski PA; Gaczynska M
    Curr Med Chem; 2006; 13(2):155-65. PubMed ID: 16472211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomic force microscopy of proteasome assemblies.
    Gaczynska M; Osmulski PA
    Methods Mol Biol; 2011; 736():117-32. PubMed ID: 21660725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin allosterically inhibits the proteasome.
    Osmulski PA; Gaczynska M
    Mol Pharmacol; 2013 Jul; 84(1):104-13. PubMed ID: 23619386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting a role of a charge and conformation of Tat2 peptide in allosteric regulation of 20S proteasome.
    Witkowska J; Karpowicz P; Gaczynska M; Osmulski PA; Jankowska E
    J Pept Sci; 2014 Aug; 20(8):649-56. PubMed ID: 24819612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy.
    Frezza M; Schmitt S; Dou QP
    Curr Top Med Chem; 2011 Dec; 11(23):2888-905. PubMed ID: 21824109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities.
    Song R; Qiao W; He J; Huang J; Luo Y; Yang T
    J Med Chem; 2021 Mar; 64(6):2851-2877. PubMed ID: 33656892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule inhibitors of proteasome activity.
    Gaczynska M; Osmulski PA
    Methods Mol Biol; 2005; 301():3-22. PubMed ID: 15917622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.
    Genin E; Reboud-Ravaux M; Vidal J
    Curr Top Med Chem; 2010; 10(3):232-56. PubMed ID: 20166955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allostery Modulates Interactions between Proteasome Core Particles and Regulatory Particles.
    Coffino P; Cheng Y
    Biomolecules; 2022 May; 12(6):. PubMed ID: 35740889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
    Dick LR; Fleming PE
    Drug Discov Today; 2010 Mar; 15(5-6):243-9. PubMed ID: 20116451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design.
    Carmony K; Lee W; Kim KB
    Chembiochem; 2016 Nov; 17(22):2115-2117. PubMed ID: 27605113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The persisting challenge of selective and specific proteasome inhibition.
    Groll M; Huber R; Moroder L
    J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.